ERBB2 and neoplasm: IL-2 effect on the anti-tumor effects of TRZ in MBC in pts who had progressed on or within 12 months of receiving a TRZ-containing regimen. Secondary objectives were to measure ADCC against HER2 over-expressing cells, and to measure serum cytokines